MNLO - Menlo Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.13
-0.20 (-2.73%)
At close: 4:00PM EDT

7.13 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close7.33
Open7.26
Bid7.00 x 800
Ask7.40 x 1400
Day's Range7.04 - 7.38
52 Week Range3.74 - 12.00
Volume79,196
Avg. Volume94,200
Market Cap165.831M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.37
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.80
Trade prices are not sourced from all markets
  • GlobeNewswire12 hours ago

    Menlo Therapeutics to Present at the Class of 2018 Biotech IPOs Investor Day

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the Class of 2018 Biotech IPOs Investor Day on Friday April 26, 2018 at 11:00 a.m. ET in New York, New York. The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • Consider These 3 Falling Knives
    GuruFocus.com17 days ago

    Consider These 3 Falling Knives

    Wall Street issued a buy recommendation rating for all three stocks, increasing the likelihood of them outperforming the S&P 500 Index over the next 52 weeks. Warning! GuruFocus has detected 2 Warning Sign with CTMX. Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives.

  • ACCESSWIRE28 days ago

    EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

    NEW YORK, NY / ACCESSWIRE / March 25, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, ...

  • GlobeNewswire28 days ago

    Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for the treatment of pruritus associated with prurigo nodularis (PN) in the Journal of the American Academy of Dermatology (JAAD). In this randomized, double-blind, placebo-controlled study, 128 patients with chronic, treatment-refractory PN for more than 6 weeks received serlopitant, 5 mg, or placebo orally once daily for 8 weeks.

  • GlobeNewswirelast month

    Menlo Therapeutics Announces New Board Member Elisabeth Sandoval

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has been appointed as a member of Menlo’s Board of Directors, effective immediately.  Ms. Sandoval currently serves as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, previously served as Chief Commercial Officer of KYTHERA Biopharmaceuticals, and prior to that role, as Vice President of Global Marketing for Allergan. In addition to her responsibilities as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a clinical stage company focused on developing novel therapeutic antibodies for the treatment of migraine, Ms. Sandoval is also responsible for developing and leading the company’s medical affairs, investor relations, corporate communications and business development functions.  Before joining Alder, she was Chief Commercial Officer for KYTHERA Biopharmaceuticals, where she led the commercial strategy and execution including the hiring and development of all commercial functions and launch of a first-in-class product prior to KYTHERA’s acquisition by Allergan.

  • GlobeNewswirelast month

    Menlo Therapeutics to Present at the 31st Annual ROTH Conference

    The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. The company’s clinical development program for serlopitant includes two ongoing Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis, a planned Phase 3 program for the treatment of pruritus associated with psoriasis, and a Phase 2 clinical trial for the treatment of chronic pruritus of unknown origin.

  • GlobeNewswire2 months ago

    Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

    “We are making solid progress in the clinical development of serlopitant for pruritus associated with prurigo nodularis (PN), our most advanced indication.  Both Phase 3 PN trials are enrolling well, and we expect results from these trials in the first half of 2020,” stated Steve Basta, Chief Executive Officer of Menlo Therapeutics.  “If our PN trials are successful, we expect to file an NDA for our first indication in 2020.

  • GlobeNewswire2 months ago

    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

    To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (MNLO) pursuant or traceable to the Company’s Initial Public Offering closed on January 29, 2018. If you purchased or otherwise acquired Menlo securities pursuant to the initial public offering, your rights may be affected by this action. In its January 2018 IPO, Menlo issued over 8 million shares at $17 per share, raising over $136 million in gross proceeds.

  • GlobeNewswire3 months ago

    Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting

    The abstract, “Serlopitant Reduced Pruritus Associated with Psoriasis in Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial” will be presented as part of Late Breaking Research: Clinical Trials on Saturday, March 2 between 1:00 p.m. and 4:00 p.m. in Ballroom A. In addition, a second abstract, “Improvement of Itch and Pain in Patients with Prurigo Nodularis Treated with Serlopitant: Secondary analysis of Phase 2 Clinical Trial” was accepted as an oral presentation and online e-poster.  Presentations will be held on Friday, March 1 and Saturday, March 2.

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA for the Treatment of Pruritus Associated with Prurigo Nodularis

    REDWOOD CITY, Calif., Jan. 15, 2019 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the.

  • GlobeNewswire3 months ago

    Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation

    In January 2018, Menlo Therapeutics Inc. (MNLO) completed its IPO, selling over 8 million shares of common stock at $17.00 per share. The plaintiff claims that in its registration statement, Menlo Therapeutics Inc. stated that if the results of its Phase 2 clinical trials for the treatment of pruritus are promising, the company would "rapidly advance into Phase 3 clinical trials" and would use the net proceeds from the IPO to fund such trials.

  • What does Menlo Therapeutics Inc.’s (NASDAQ:MNLO) Balance Sheet Tell Us About Its Future?
    Simply Wall St.4 months ago

    What does Menlo Therapeutics Inc.’s (NASDAQ:MNLO) Balance Sheet Tell Us About Its Future?

    Menlo Therapeutics Inc. (NASDAQ:MNLO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MNLO Read More...

  • ACCESSWIRE4 months ago

    Lawsuit for Investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) announced by Shareholders Foundation

    SAN DIEGO, CA / ACCESSWIRE / December 17, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) over alleged ...

  • Menlo Therapeutics Inc. (MNLO): Are Hedge Funds Right About This Stock?
    Insider Monkey4 months ago

    Menlo Therapeutics Inc. (MNLO): Are Hedge Funds Right About This Stock?

    Is Menlo Therapeutics Inc. (NASDAQ:MNLO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]

  • GlobeNewswire4 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

    To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (MNLO) pursuant or traceable to the Company’s Initial Public Offering closed on January 29, 2018. If you purchased or otherwise acquired Menlo securities pursuant to the initial public offering, your rights may be affected by this action. In its January 2018 IPO, Menlo issued over 8 million shares at $17 per share, raising over $136 million in gross proceeds.

  • Business Wire4 months ago

    Robbins Arroyo LLP: Menlo Therapeutics Inc. (MNLO) Misled Shareholders According to Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Menlo Therapeutics Inc. (MNLO) filed a class action complaint against the company's officers and directors for alleged violations of the Securities Act of 1933 in connection with Menlo's January 29, 2018 initial public offering ("IPO"). Menlo, a late-stage biopharmaceutical company, develops and commercializes serlopitant for the treatment of itching associated with dermatologic conditions in the United States.

  • GlobeNewswire4 months ago

    Market Trends Toward New Normal in Apptio, Menlo Therapeutics, Tanger Factory Outlet Centers, Cedar Realty Trust, Toll Brothers, and II-VI — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Inc.

    NEW YORK, Dec. 11, 2018 -- Levi & Korsinsky announces it has commenced an investigation of Menlo Therapeutics, Inc. (“Menlo” or “the Company”) (NASDAQGS: MNLO) concerning.

  • GlobeNewswire4 months ago

    Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis

    The trial successfully met the secondary endpoint of WI-NRS responder rate at week 4.  At week 4, 21% of patients treated with serlopitant achieved a 4-point or greater improvement on the WI-NRS vs. 11% of patients treated with placebo (p=0.039).  Assessment of the secondary endpoints of the absolute change in WI-NRS from baseline to day 7 and day 3 for serlopitant compared to placebo showed a greater numerical, but not statistically significant, improvement for the serlopitant group.  At every assessed time point in the trial (daily in week 1 and average weekly scores through week 8), the serlopitant treated group demonstrated greater numerical improvement than the placebo group in both the WI-NRS 4-point responder analysis and in the mean change in WI-NRS from baseline. Serlopitant was well-tolerated in this clinical trial.  No serious adverse events were reported for serlopitant treated patients.  Treatment-emergent adverse events assessed as likely related to treatment were observed with similar frequency in both groups (4.0% for placebo and 4.9% for serlopitant).  The consolidated safety summary for serlopitant now includes more than 1,600 evaluable patients, including patients who have received treatment for up to one year.

  • This year's Bay Area IPO batch remains up 44% despite market turbulence
    American City Business Journals5 months ago

    This year's Bay Area IPO batch remains up 44% despite market turbulence

    Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.

  • GlobeNewswire5 months ago

    Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Menlo Therapeutics to Participate in the 30th Annual Piper Jaffray Healthcare Conference

    The fireside chat will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • ACCESSWIRE5 months ago

    INVESTOR ALERT: Kaskela Law LLC Announces Investigation of Menlo Therapeutics Inc. on Behalf of Investors - MNLO

    RADNOR, PA / ACCESSWIRE / November 14, 2018 / Kaskela Law LLC is investigating Menlo Therapeutics Inc. (NASDAQ: MNLO) ("Menlo" or the "Company") on behalf of investors. Menlo is a late-stage ...